Antisense And Rnai Therapeutics Market for the antisense and RNAi therapeutics market was valued at USD 2270.7 million in 2020 and is expected to generate revenue of around USD 2459.2 million by end of 2030, growing at an approximate CAGR of around 8.3% between 2019 and 2029. Antisense and RNAi therapeutics are therapeutic treatments having the potential to treat diseases such as chronic liver and cardiovascular diseases, and other rare diseases. Antisense RNAi was the largest technology segment in 2018 due to technological advancement in the healthcare sector. Antisense technology is a method that can stop protein production. Antisense technology can be used to design new therapeutics for certain new diseases. The principle behind is antisense nucleic acid sequence base pairs with complementary sense RNA strand and avoids from being translated into a protein. Based on the triggering of the RNA molecules this technology is segmented into siRNA and miRNA. Antisense and RNAi therapeutics services are applicable in the treatment of a wide range of diseases that target nucleic acid and affect the cell growth cycle. miRNA has the ability to restore gene expression and correct protein production, which is attracting more pharma companies to grow in this sector. siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which is attributive for the largest share of oncology applications.

Market Segmentation:

The global antisense and RNAi therapeutics market is segmented by technology into RNAi and antisense RNA)). The RNAi is further divided into miRNA and siRNA.  By route of administration, the market is segregated into pulmonary, intravenous, intradermal, intraperitoneal, topical, and others. By indication the market is categorized into oncology, cardiovascular diseases, renal diseases, neurodegenerative diseases, respiratory diseases, genetic diseases, infectious diseases, and others. By end-user, the market is classified into hospitals, research institutes, and others. By geography, the antisense and rnai therapeutics market is divided into Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa. 

Market Dynamics and Factors:

Owing to an increase in the number of geriatric population that suffers from acute illness to chronic diseases, cancer, and cardiovascular diseases has promoted the growth of Antisense & RNAi therapeutics market. The toxic effects caused during the treatment for the use of this technology have hampered the antisense and RNAi therapeutics market growth. Extensive R&D programs carried out in this sector to develop an efficient method for the delivery of RNA silencing therapeutic products are anticipated to propel the market growth. Government sanctions and rejections faced by companies from the regulatory bodies are the major challenges for the growth of the antisense and Rnai therapeutics market.

Geographic Analysis:

Asia Pacific will show significant improvement in the antisense & RNAi therapeutics market due to increasing diseases like AIDS and other chronic diseases. Receiving support from the government through regulation and provisions to boost up research activities and clinical trials will encourage the global antisense and RNAi therapeutics market. Antisense RNA technology accounted for the largest share in market revenue in 2017 owing to advantages associated with this technology over RNA interference. North America is estimated considered a key market due to the number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made significantly high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of antisense and RNAi therapeutics market.

Competitive Scenario:

The major players in the global antisense and RNAi therapeutics market are GSK, Sanofi-Genzyme, Alnylam Pharmaceuticals, Marina Biosciences, Benitec Biopharma, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akcea Therapeutics, Quark Pharmaceuticals, and Gene Signal.

Antisense And RNAi Therapeutics Market Report Scope